For decades, the foundation of **Herpes Simplex Virus treatment** has relied on a small family of nucleoside analogue antivirals. While highly effective for most people, the emergence of **drug resistance**, particularly in immunocompromised patient populations—suchg as transplant recipients or individuals with advanced HIV—presents a critical and growing clinical challenge. When...